Application Value of 68Ga-FAPI PET/CT in the Evaluation of Myelofibrotic Diseases
Ya Liu, Xue Li, Li Jing, Chunmei Guo, Zibei Wan, Feiyu Zhang, Pengqiang Wu, Zhanwen Huang- Radiology, Nuclear Medicine and imaging
- General Medicine
Purpose
Fibroblast activation protein is highly expressed in neoplastic lesions and various fibrotic tissues, making it an attractive target for disease evaluation. 68Ga-labeled fibroblast activation protein inhibitor (FAPI), a new tumor interstitial imaging agent, holds promise for evaluating myelofibrosis. Therefore, this study aimed to use 68Ga-FAPI PET/CT for the noninvasive visualization and quantification of the extent of myelofibrosis.
Patients and Methods
This was a prospective clinical study involving 22 patients with myelofibrosis who underwent 68Ga-FAPI PET/CT. The uptake of 68Ga-FAPI was measured in their respective bone marrow and spleen, and the obtained imaging findings were compared with laboratory, cytogenetic, and histopathological data.
Results
68Ga-FAPI uptake in the bone marrow was significantly and positively correlated with the myelofibrosis grade (
Conclusions
68Ga-FAPI PET/CT shows promise as a method for visualizing and quantifying myelofibrosis, providing suitable sites for bone marrow biopsy. The extent of 68Ga-FAPI uptake by bone marrow increases with the progression of myelofibrosis, thus it is a simple and noninvasive measurement that can be used to evaluate the progression of myelofibrosis. Nevertheless, although 68Ga-FAPI PET/CT has demonstrated a potential value in prognostic assessment, further confirmation is needed.